financetom
Business
financetom
/
Business
/
StanChart third-quarter profit more than doubles, beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
StanChart third-quarter profit more than doubles, beats estimates
Nov 3, 2024 2:38 PM

HONG KONG/LONDON (Reuters) -Standard Chartered's ( SCBFF ) quarterly profit more than doubled from a year ago, topping analyst estimates, as it recovered from China-related impairments while wealth and markets businesses bolstered the emerging-market focused lender's revenue. StanChart, which earns most of its revenue in Asia, said pretax profit for the third quarter reached $1.72 billion, above the $1.49 billion average of 17 analyst estimates compiled by the bank.

The profit compared with $633 million a year earlier, when StanChart took a nearly $1 billion combined hit from its exposure to China's real estate and banking sectors. The London-headquartered bank, which shook off the impact of the China-related impairments seen last year, did not announce a fresh share buyback for the quarter, unlike rival HSBC.

StanChart upgraded its forecast for return of tangible equity - a performance metric - to close to 13% in 2026 from a previous target of 12% in 2026 and onwards.

The bank is "doubling investment" in its wealth management business, and will continue to "reshape" its mass retail business to focus on future affluent and international clients, Group Chief Executive Bill Winters said in a statement.

StanChart joined European peers in making robust progress on sustaining profits amid falling rates.

HSBC reported a 10% quarterly year-on-year profit increase on Tuesday, sending its shares to an at least six-year high as investors turned bullish on its outlook.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cellectar Biosciences Signs Isotope Supply Agreement With Nusano
Cellectar Biosciences Signs Isotope Supply Agreement With Nusano
Jun 26, 2025
08:35 AM EDT, 06/26/2025 (MT Newswires) -- Cellectar Biosciences ( CLRB ) said Thursday it signed a multi-year agreement with physics firm Nusano for the supply of iodine-125 and actinium-225 for clinical studies and future commercial needs. The isotopes will provide the necessary clinical development supply for the company's clinical-stage programs, including CLR 125 for triple-negative breast cancer and CLR...
Blue Moon Metals Awards Mining Contract for Construction of Portal and Exploration Decline for Its Mine in Mariposa County, California
Blue Moon Metals Awards Mining Contract for Construction of Portal and Exploration Decline for Its Mine in Mariposa County, California
Jun 26, 2025
08:48 AM EDT, 06/26/2025 (MT Newswires) -- Blue Moon Metals ( BMOOF ) , which lost 2.6% on Wednesday, awarded a contract to Small Mine Development for the construction of a portal and decline to enable underground mineral exploration activities at the Blue Moon volcanogenic massive sulphide deposit in Mariposa County, California. A company statement noted that the construction work...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution
Jun 26, 2025
08:37 AM EDT, 06/26/2025 (MT Newswires) -- Altimmune ( ALT ) said Thursday that its phase 2b trial of its product candidate pemvidutide has met its primary endpoint with statistically significant metabolic dysfunction-associated steatohepatitis, or MASH, resolution. The company said pemvidutide showed significant MASH effects and weight loss at 24 weeks. An intent-to-treat analysis showed that MASH resolution without worsening...
Copyright 2023-2026 - www.financetom.com All Rights Reserved